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Abstract
Background: The clinical course of breast cancer is difficult to predict on the basis of established
clinical and pathological prognostic criteria. Given the genetic complexity of breast carcinomas, it
is not surprising that correlations with individual genetic abnormalities have also been
disappointing. The use of gene expression profiles could result in more accurate and objective
prognostication.
Results:  To this end, we used real-time quantitative RT-PCR assays to quantify the mRNA
expression of a large panel (n = 47) of genes previously identified as candidate prognostic molecular
markers in a series of 100 ERα-positive breast tumor samples from patients with known long-term
follow-up. We identified a three-gene expression signature (BRCA2, DNMT3B and CCNE1) as an
independent prognostic marker (P = 0.007 by univariate analysis; P = 0.006 by multivariate analysis).
This "poor prognosis" signature was then tested on an independent panel of ERα-positive breast
tumors from a well-defined cohort of 104 postmenopausal breast cancer patients treated with
primary surgery followed by adjuvant tamoxifen alone: although this "poor prognosis" signature
was associated with shorter relapse-free survival in univariate analysis (P = 0.029), it did not persist
as an independent prognostic factor in multivariate analysis (P = 0.27).
Conclusion:  Our results confirm the value of gene expression signatures in predicting the
outcome of breast cancer.
Background
Breast carcinoma is the most common female cancer and
is showing an alarming year-on-year increase. Most
patients do not die as a result of the primary tumor but
from metastatic invasion. The mean 5-year relapse-free
survival rate is about 60% overall, but differs significantly
between patients with forms that rapidly metastasize and
those with less aggressive forms.
Current clinical, pathological and biological parameters,
i.e. age, menopausal status, lymph-node status, macro-
scopic tumor size, histological grade and estrogen recep-
tor status, fail to accurately predict clinical behavior.
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Breast cancer initiation and progression is a process
involving multiple molecular alterations, many of which
are reflected by changes in gene expression in malignant
cells. Many clinical studies have attempted to identify cor-
relations between altered expression of individual genes
and breast cancer outcome, but often with contradictory
results. Examples of such genes include ERBB2, CCDN1,
MYC, UPA and PAI1 [1-3]. It is thus likely that these genes
have limited predictive power when considered in isola-
tion, but that their clinical relevance may be increased
when several genes are considered together.
The recent development of effective tools for monitoring
gene expression on a large scale is providing new insights
into the involvement of gene networks and regulatory
pathways in various tumor processes [4]. It has also led to
the discovery of new diagnostic and prognostic indicators,
and to the identification of new molecular targets for drug
development [5]. These tools include cDNA microarrays,
which can be used to explore the expression of thousands
of genes at a time, and real-time RT-PCR assays for more
accurate and quantitative studies of the expression of a
smaller number of selected candidate genes.
In this study, we used real-time quantitative RT-PCR
assays to quantify the mRNA expression of 47 candidate
prognostic molecular markers in a series of 100 ERα-pos-
itive breast tumor samples. We identified a three-gene
expression signature (BRCA2,  DNMT3B  and  CCNE1)
associated with poor clinical outcome. We then tested this
"poor prognosis" signature on an independent panel of
ERα-positive breast tumor samples from a well-defined
cohort of 104 postmenopausal breast cancer patients
treated with primary surgery followed by adjuvant
tamoxifen alone with known long-term follow-up.
Materials and Methods
Patients and samples
We analyzed samples from two series of women with pri-
mary unilateral ERα-positive breast carcinoma. ERα-posi-
tive status was determined at both the protein level by the
Dextran-coated charcoal method until 1988 and enzy-
matic immuno-assay thereafter, and at the mRNA level by
real-time quantitative RT-PCR assay [6].
The first series consisted of 100 women whose breast
tumors were excised at Centre René Huguenin from 1977
to 1987. The patients (mean age 58.1 years, range 34–91)
were pre- or post-menopausal (37 and 63 patients, respec-
tively). Sixty patients received adjuvant therapy, consist-
ing of chemotherapy alone in 14 cases, hormone therapy
alone in 15 cases, and both treatments in 31 cases. The
standard prognostic factors are presented in Table 1. The
median follow-up was 9.3 years (range 1.4–16.2 years).
Thirty-seven patients relapsed within 10 years after sur-
gery. The first relapse events consisted of local and/or
regional recurrences in 11 patients, metastases in 22
patients, and both events in four patients.
The second series consisted of 104 post-menopausal
women whose breast tumors were excised at Centre René
Huguenin from 1980 to 1994. The patients (mean age
70.9 years, range 54–86) all received post-operative adju-
vant hormone therapy consisting of tamoxifen (20 mg
daily for 3–5 years) and no other treatment. The standard
prognostic factors are reported in Table 2. The median fol-
low-up was 5.9 years (range 1.4–18.1 years). Thirty-one
patients relapsed within 10 years after surgery. The first
relapse events consisted of local and/or regional recur-
rences in five patients, metastases in 24 patients, and both
events in two patients.
Complete clinical, histological and biological informa-
tion was available for the two series of breast cancer
patients; no radiotherapy or chemotherapy was given
before surgery, and full follow-up took place at Centre
René Huguenin. The histological type of the tumor and
the number of positive axillary nodes were established at
the time of surgery. The malignancy of infiltrating
Table 1: Characteristics of the first series of 100 ERα-positive 
breast tumor patients, and relation to RFS
RFS
Number of 
patients
Number of 
events (%)a
P valueb
Age NS (0.68)
≤50 32 11 (34.3)
>50 68 26 (38.2)
SBR histological gradec NS (0.14)
I1 6 3  ( 1 8 . 7 )
II 51 21 (41.1)
III 26 13 (50.0)
Lymph node status 0.042
Node-negative 34 7 (20.5)
Node-positive 66 30 (45.4)
Macroscopic tumor sized NS (0.97)
≤30 mm 69 26 (37.6)
>30 mm 24 10 (41.6)
a: First relapses (local and/or regional recurrences, and/or metastases).
b: Log-rank test. NS, not significant.
c: Scarff Bloom Richardson classification. Information available for 93 
patients.
d: Information available for 93 patients.Molecular Cancer 2004, 3:37 http://www.molecular-cancer.com/content/3/1/37
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carcinomas was scored according to Scarff Bloom and
Richardson's (SBR) histoprognostic system.
Both series of tumor samples were placed in liquid nitro-
gen until total RNA extraction immediately following
surgery.
Real-time RT-PCR
(1) Theoretical basis
Quantitative values are obtained from the cycle number
(Ct value) at which the increase in fluorescent signal asso-
ciated with an exponential growth of PCR products starts
to be detected by the laser detector of the ABI Prism 7700
Sequence Detection System (Perkin-Elmer Applied Bio-
systems, Foster City, CA) using the PE Biosystems analysis
software according to the manufacturer's manuals.
The precise amount of total RNA added to each reaction
(based on optical density) and its quality (i.e. lack of
extensive degradation) are both difficult to assess. We
therefore also quantified transcripts of the gene TBP (Gen-
bank accession NM_003194) encoding for the TATA box-
binding protein (a component of the DNA-binding pro-
tein complex TFIID) as an endogeneous RNA control, and
normalized each sample on the basis of its TBP content.
Results, expressed as N-fold differences in target gene
expression relative to the TBP  gene, termed "Ntarget",
were determined by the formula: Ntarget  = 2∆Ct  sample,
where ∆Ct value of the sample was determined by sub-
tracting the average Ct value of the target gene from the
average Ct value of the TBP gene.
The Ntarget values of the samples were subsequently nor-
malized such that the Ntarget value of the tumor sample
which contained the smallest amount of target gene
mRNA in each tumor series would equal a value of 1.
(2) Primers and probes
Primers and probes for TBP and the 47 target genes were
chosen with the assistance of the computer programs
Oligo 5.0 (National Biosciences, Plymouth, MN). We
conducted searches in dbEST, htgs and nr databases to
confirm the total gene specificity of the nucleotide
sequences chosen for the primers and probes, and the
absence of single nucleotide polymorphisms. In particu-
lar, the primer pairs were selected to be unique when com-
pared with the sequences of the closely related family
member genes or of corresponding retropseudogenes. To
avoid amplification of contaminating genomic DNA, one
of the two primers or the probe was placed at the junction
between two exons. Agarose gel electrophoresis allowed
us to verify the specificity of PCR amplicons. The list of the
47 target genes tested in this study is indicated in Table 3.
(3) RNA extraction
Total RNA was extracted from frozen tumor samples by
using the acid-phenol guanidinium method. The quality
of the RNA samples was determined by electrophoresis
through agarose gels and staining with ethidium bromide,
and the 18S and 28S RNA bands were visualized under
ultraviolet light.
(4) cDNA Synthesis
Reverse transcription of total RNA was done in a final vol-
ume of 20 µL containing 1X RT buffer (500 µM each
dNTP, 3 mM MgCl2, 75 mM KCl, 50 mM Tris-HCl pH
8.3), 20 units of RNasin RNase inhibitor (Promega, Mad-
ison, WI), 10 mM DDT, 100 units of Superscript II RNase
H- reverse transcriptase (Invitrogen, Cergy Pontoise,
France), 3 µM random hexamers (Pharmacia, Uppsala,
Sweden) and 1 µg of total RNA. The samples were incu-
bated at 20°C for 10 min and 42°C for 30 min, and
reverse transcriptase was inactivated by heating at 99°C
for 5 min and cooling at 5°C for 5 min.
(5) PCR amplification
All PCR reactions were performed using a ABI Prism 7700
Sequence Detection System (Perkin-Elmer Applied Bio-
systems). PCR was performed using either the TaqMan®
PCR Core Reagents kit or the SYBR® Green PCR Core
Table 2: Characteristics of the second series of 104 ERα-positive 
postmenopausal breast tumor patients, and relation to RFS
RFS
Number of 
patients
Number of 
events (%)a
P valueb
Age NS (0.92)
≤70 52 17 (32.6)
>70 52 14 (26.9)
SBR histological gradec 0.0005
I1 3 0
II 67 17 (25.3)
III 23 13 (56.5)
Lymph node status NS (0.17)
Node-negative 17 2 (11.7)
Node-positive 87 29 (33.3)
Macroscopic tumor sized 0.015
≤30 mm 71 16 (22.5)
>30 mm 31 14 (45.1)
a: First relapses (local and/or regional recurrences, and/or metastases)
b: Log-rank test. NS, not significant.
c: Scarff Bloom Richardson classification. Information available for 103 
patients.
d: Information available for 102 patients.Molecular Cancer 2004, 3:37 http://www.molecular-cancer.com/content/3/1/37
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Reagents kit (Perkin-Elmer Applied Biosystems). The ther-
mal cycling conditions comprised an initial denaturation
step at 95°C for 10 min and 50 cycles at 95°C for 15 s and
65°C for 1 min.
Statistical Analysis
The distributions of the gene mRNA levels were character-
ized by their median values and ranges. Relationships
between mRNA levels of the different target genes and
Table 3: List of the 47 target genes selected
Genesa Genbank accession number Chromosomal location Description
AR NM_000044 Xq11.2-q12 Androgen receptor
AREG NM_001657 4q13-q21 Amphiregulin
ARHC/RhoC NM_175744 1p13.1 Ras homolog gene family, member C
BCL2 NM_000633 18q21.3 B-cell CLL/lymphoma 2
BRCA1 NM_007294 17q21 Breast cancer 1, early onset
BRCA2 NM_000059 13q12.3 Breast cancer 2, early onset
CAV1 NM_001753 7q31.1 Caveolin 1
CCND1 NM_053056 11q13 Cyclin D1
CCNE1 NM_001238 19q12 Cyclin E1
CD44 NM_000610 11p13 CD44 antigen
CDH1 NM_004360 16q22.1 Cadherin 1 (E-cadherin)
CGA NM_000735 6q12-q21 Glycoprotein hormones, alpha polypeptide
CGB NM_000737 19q13.32 Chorionic gonadotropin, beta polypeptide
CP/Ceruloplasmin NM_000096 3q23-q25 Ceruloplasmin
CXCL12 NM_000609 10q11.1 Chemokine (C-X-C motif) ligand 12
CXCR4 NM_003467 2q21 Chemokine (C-X-C motif) receptor 4
DNMT3B NM_006892 20q11.2 DNA (cytosine-5-)-methyltransferase 3 beta
EGFR/ERBB1 NM_005228 7p12 Epidermal growth factor receptor
ERBB2 NM_004448 17q21.1 ErbB2
ERBB3 NM_001982 12q13 ErbB3
ERBB4 NM_005235 2q33.3-q34 ErbB4
ESR1/ERα NM_000125 6q25.1 Estrogen receptor 1 (alpha)
ESR2/ERβ NM_001437 14q Estrogen receptor 2 (beta)
ETV4/PEA3/E1AF NM_001986 17q21 Ets variant gene 4
HAS2 NM-005328 8q24.12 Hyaluronan synthase 2
HMMR/RHAMM NM_012484 5q33.2-qter Hyaluronan-mediated mobility receptor
KRT19 NM_002276 17q21.2 Keratin 19
MKI67 NM_002417 10q25-qter Antigen identified by monoclonal antibody Ki-67
MYC NM_002467 8q24.12-q24.13 c-myc oncogene
p14/ARF NM_058195 9p21 Alternative reading frame p14 (p14ARF)
p15/CDKN2B NM_004936 9p21 Cyclin-dependent kinase inhibitor 2B (p15 CDK inhibitor)
p16/CDKN2A NM_000077 9p21 Cyclin-dependent kinase inhibitor 2A (p16 CDK inhibitor)
PGR/PR NM_000926 11q22-q23 Progesterone receptor
PLAU/UPA NM_002658 10q24 Plasminogen activator, urokinase
PTGS2/COX2 NM_000963 1q25.2-q25.3 Prostaglandin-endoperoxide synthase 2
PTTG1/Securin NM_004219 5q35.1 Pituitary tumor-transforming 1
RB1 NM_000321 13q14.2 Retinoblastoma 1
SERPINB2/PAI2 NM_002575 18q21.3 Plasminogen activator inhibitor type 2
SERPINB5/Maspin NM_002639 18q21.3 Maspin
SERPINE1/PAI1 NM_000602 7q21.3-q22 Plasminogen activator inhibitor type 1
SPP1/Osteopontin NM_000582 4q21-q25 Secreted phosphoprotein 1
SRC NM_005417 20q12-q13 c-src oncogene
TERT NM_003219 5p15.33 Telomerase reverse transcriptase
TFF1/pS2 NM_003225 21q22.3 Trefoil factor 1
TIAM1 NM_003253 21q22.11 T-cell lymphoma invasion and metastasis 1
TOP2A NM_001067 17q21-q22 Topoisomerase (DNA) II alpha 170 kDa
XLKD1/LYVE-1 NM_006691 11p15 Extracellular link domain containing 1
aLocusLink symbolMolecular Cancer 2004, 3:37 http://www.molecular-cancer.com/content/3/1/37
Page 5 of 10
(page number not for citation purposes)
comparison between the target gene mRNA levels and the
clinical parameters were estimated using nonparametric
tests: the Mann-Whitney U test (link between 1 qualitative
parameter and 1 quantitative parameter) and the Spear-
man rank correlation test (link between 2 quantitative
parameters). Differences between the two populations
Table 4: Relationships between the prognostic (+/- relapses) and the mRNA levels of the 47 selected genes in 100 ERα-positive breast 
tumors
GENES Tumors without relapses (n = 63) Tumors with relapses (n = 37) Pa ROC-AUCb
BRCA2 4.6 (1.0–12.4)c 7.1 (1.9–18.8) 0.0011 0.696 (0.59–0.80)d
DNMT3B 3.0 (1.0–13.6) 4.6 (1.2–17.4) 0.0015 0.690 (0.58–0.80)
CCNE1 6.2 (1.0–36.9) 8.9 (3.1–82.5) 0.0038 0.674 (0.57–0.78)
HMMR/RHAMM 18.9 (1.0–163.5) 30.1 (3.8–186.5) 0.0068 0.663 (0.55–0.77)
MKI67 9.1 (1.0–49.8) 14.4 (1.7–54.9) 0.016 0.645 (0.53–0.75)
TERT 18.7 (1.0–121.9) 22.1 (1.8–135.8) 0.049 0.618 (0.50–0.73)
TOP2A 40.9 (1.0–306) 55.6 (6.1–317) NS 0.605 (0.49–0.72)
PLAU/UPA 4.6 (1.0–36.4) 5.8 (1.4–34.0) NS 0.588 (0.47–0.70)
CGB 4.2 (1.0–31.2) 6.4 (1.4–32.8) NS 0.579 (0.46–0.70)
ERBB2 14.0 (1.0–175) 16.3 (4.2–179.8) NS 0.573 (0.46–0.69)
BRCA1 11.9 (1.0–44.5) 14.3 (1.8–62.5) NS 0.569 (0.45–0.69)
CXCR4 6.5 (1.0–40.5) 7.5 (1.5–71.5) NS 0.569 (0.45–0.68)
PTTG1/Securin 1.9 (1.0–26.9) 1.9 (1.2–33.1) NS 0.566 (0.45–0.68)
SRC 2.6 (1.0–4.3) 2.9 (1.4–10.2) NS 0.561 (0.45–0.67)
p16/CDKN2A 3.4 (1.0–107.4) 4.4 (1.1–136.7) NS 0.560 (0.44–0.68)
AREG 89.3 (1.0–5667) 110.1 (3.1–3301) NS 0.555 (0.44–0.67)
SERPINE1/PAI1 3.8 (1.0–21.4) 4.5 (1.3–21.8) NS 0.554 (0.44–0.67)
ERBB3 2.6 (1.0–10.7) 3.3 (1.2–13.4) NS 0.552 (0.44–0.67)
SERPINB5/Maspin 12.6 (1.0–321) 16.4 (1.0–718) NS 0.551 (0.43–0.67)
CDH1 11.3 (1.0–32.6) 13.9 (1.5–33.3) NS 0.549 (0.43–0.67)
p15/CDKN2B 3.5 (1.0–16.2) 4.2 (1.0–34.9) NS 0.548 (0.43–0.67)
SPP1/Osteopontin 43.3 (1.0–1403) 56.8 (2.1–941) NS 0.548 (0.42–0.68)
ETV4/PEA3/E1AF 5.1 (1.0–49.3) 6.9 (1.8–62.0) NS 0.545 (0.43–0.66)
CP/Ceruloplasmin 33.5 (1.0–9815) 81.5 (1.0–33943) NS 0.545 (0.42–0.67)
SERPINB2/PAI2 13.0 (1.0–498) 15.3 (1.0–1652) NS 0.535 (0.42–0.65)
TIAM1 13.6 (1.0–55.9) 13.3 (3.9–83.2) NS 0.526 (0.41–0.64)
RB1 4.2 (1.0–7.4) 4.3 (1.5–7.7) NS 0.520 (0.40–0.64)
AR 54.2 (1.0–219) 64.8 (1.0–211) NS 0.518 (0.40–0.64)
HAS2 6.5 (1.0–40.8) 6.4 (1.4–31.9) NS 0.516 (0.40–0.63)
TFF1/pS2 1772 (1.0–138 545) 1783 (3–55 878) NS 0.509 (0.39–0.62)
ESR2/ERβ 28.2 (1.0–368) 25.3 (1.4–219) NS 0.500 (0.38–0.62)
ERBB4 141 (1.0–1489) 143 (2.1–1062) NS 0.483 (0.37–0.60)
KRT19 14.4 (1.6–99.1) 10.8 (1.0–57.1) NS 0.482 (0.36–0.60)
ESR1/ERα 25.5 (1.0–508) 21.7 (1.2–498) NS 0.479 (0.36–0.60)
CXCL12 12.1 (1.3–36.1) 9.6 (1.0–30.5) NS 0.464 (0.35–0.58)
MYC 8.1 (1.0–35.5) 7.5 (1.0–51.2) NS 0.464 (0.35–0.58)
EGFR/ERBB1 8.3 (1.2–108) 6.2 (1.0–66.8) NS 0.462 (0.34–0.58)
ARHC/RhoC 6.9 (1.0–192) 6.3 (1.0–17.2) NS 0.458 (0.34–0.58)
p14/ARF 4.9 (1.4–68.1) 4.4 (1.0–61.2) NS 0.457 (0.34–0.57)
XLKD1/LYVE-1 4.5 (1.4–10.9) 3.7 (1.0–10.7) NS 0.448 (0.33–0.57)
CD44 3.1 (1.2–9.6) 2.7 (1.0–8.4) NS 0.440 (0.32–0.56)
CGA 17.6 (1.0–16 552) 6.4 (1.0–5 836) NS 0.425 (0.31–0.54)
CAV1 7.4 (1.1–30.7) 5.6 (1.0–26.6) NS 0.422 (0.31–0.54)
BCL2 4.9 (1.2–13.3) 3.2 (1.0–11.8) NS 0.415 (0.30–0.53)
PGR/PR 277 (1.0–8 034) 97 (1.0–4 551) NS 0.412 (0.29–0.53)
PTGS2/COX2 4.6 (1.0–154) 3.0 (1.0–14.8) NS 0.397 (0.28–0.51)
CCND1 6.3 (1.2–45.3) 4.0 (1.0–21.3) 0.042 0.378 (0.26–0.50)
a:P value, Mann-Whitney U test ; NS, not significant
b:ROC (Receiver Operating Characteristics) – AUC (Area Under Curve) analysis
c:Median (range) of gene mRNA levels
d:AUC value (95% confidence interval)Molecular Cancer 2004, 3:37 http://www.molecular-cancer.com/content/3/1/37
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were judged significant at confidence levels greater than
95% (p < 0.05).
To visualize the efficacy of a molecular marker to discrim-
inate two populations (in the absence of an arbitrary cut-
off value), we summarized the data in a ROC (receiver
operating characteristic) curve [7]. This curve plots the
sensibility (true positives) on the Y axis against 1 – the
specificity (false positives) on the X axis, considering each
value as a possible cutoff value. The AUC (area under
curves) was calculated as a single measure for the discrim-
inate efficacy of a molecular marker. When a molecular
marker has no discriminative value, the ROC curve will lie
close to the diagonal and the AUC is close to 0.5. When a
test has strong discriminative value, the ROC curve will
move up to the upper left-hand corner (or to the lower
right-hand corner) and the AUC will be close to 1.0 (or 0).
Hierarchical clustering was performed using the GenA-
NOVA software [8].
Relapse-free survival (RFS) was determined as the interval
between diagnosis and detection of the first relapse (local
and/or regional recurrences, and/or metastases).
Survival distributions were estimated by the Kaplan-Meier
method [9], and the significance of differences between
survival rates was ascertained using the log-rank test [10].
Cox's proportional hazards regression model [11] was
used to assess prognostic significance.
Results
mRNA expression of 47 genes in 100 ERα-positive breast 
tumors
The results for the 47 genes are summarized in table 4,
with medians and ranges of mRNA levels in patients who
relapsed (n = 37) and those who did not (n = 63).
Seven genes showed significantly different expression
according to relapse status (P < 0.05), namely BRCA2,
DNMT3B, CCNE1, HMMR/RHAMM, MKI67, TERT and
CCND1. The prognostic performance of these 7 genes was
also assessed using ROC-AUC analysis. BRCA2 emerged as
the most discriminatory marker of relapse status (ROC-
AUC, 0.696). The mRNA expression of this gene, as well
as DNMT3B, CCNE1, HMMR/RHAMM, MKI67 and TERT,
was higher in patients who relapsed than in patients who
did not relapse, while only CCND1 mRNA expression was
lower in patients who relapsed.
On hierarchically clustering the tumor samples according
to the expression of the three most discriminatory genes
i.e. the genes with the highest ROC-AUC values (BRCA2,
DNMT3B  and  CCNE1, ROC-AUC: 0.696, 0.690 and
0.674, respectively), the patient population fell into two
subgroups (65 and 35 subjects, respectively) with signifi-
cantly different relapse-free survival curves (log-rank test,
P = 0.007; Figure 1A) (5-year RFS rate 66.9% ± 8.1 versus
83.9% ± 4.6; 10-year RFS rate 41.0% ± 8.7 versus 67.0% ±
6.6).
The prognostic value of a two-gene expression signature
based on only BRCA2 and DNMT3B was lower than that
of the three-gene expression signature. The addition of
HMMR/RHAMM and/or MKI67 to the three-gene signa-
ture provided no additional prognostic value.
Using a Cox proportional hazards model, we also assessed
the prognostic value, for RFS, of parameters that were sig-
nificant or near-significant (P < 0.2) in univariate analysis,
i.e. SBR grade, lymph-node status (Table 1) and the three-
gene expression signature (Figure 1A). Only the prognos-
Relationship between RFS and the three-gene expression sig- nature in the initial series of 100 ERα-positive breast tumor  samples (A) and in an independent series of 104 ERα-positive  postmenopausal breast tumor samples (B) Figure 1
Relationship between RFS and the three-gene expression sig-
nature in the initial series of 100 ERα-positive breast tumor 
samples (A) and in an independent series of 104 ERα-positive 
postmenopausal breast tumor samples (B).
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tic significance of the three-gene expression signature per-
sisted [P = 0.006; regression coefficient = 0.86; relative risk
(95% confidence interval) = 2.37 (1.27–4.43)]. The prog-
nostic significance of these three parameters for RFS, cal-
culated in terms of the relative risk, did not change after
adjustment for age and macroscopic tumor size (data not
shown).
Validation of the three-gene expression signature in an 
independent series of 104 ERα-positive postmenopausal 
breast tumor samples
The results for each of the three genes are summarized in
table 5, with medians and ranges of mRNA levels in the 31
patients who relapsed and the 73 patients who did not
relapse, as well as ROC-AUC values. As in the initial
tumor series, BRCA2, DNMT3B and CCNE1 mRNA levels
were significantly higher in patients who relapsed than in
those who did not relapse.
On hierarchical clustering of the samples, the three-gene
expression signature dichotomized the 104 patients into
two subgroups (n = 30 and n = 74, respectively) of similar
sizes to those of the initial patient population (n = 35 and
n = 65, respectively).
The "poor prognosis" signature was again associated with
shorter relapse-free survival in this independent tumor
series (log-rank test, P = 0.029; Figure 1B) (5-year RFS
59.2% ± 9.1 versus 80.7% ± 4.8; 10-year RFS 51.2% ± 9.50
versus 70.4% ± 6.5).
Multivariate analysis based on a Cox proportional hazards
model showed that, among the parameters that were sig-
nificant or near-significant (P < 0.2) in univariate analysis,
i.e. SBR grade, lymph-node status, macroscopic tumor size
(Table 2) and the three-gene expression signature (Figure
1B), only SBR grade was an independent predictor of RFS
(P = 0.00023); the three-gene expression signature only
showed a trend towards significance (P = 0.27).
Discussion
We used real-time quantitative RT-PCR assays to quantify
the mRNA expression of 47 genes previously identified as
candidate prognostic molecular markers in 100 ERα-pos-
itive breast tumor samples. We identified a three-gene
expression signature (BRCA2, DNMT3B and CCNE1) with
independent prognostic significance in breast cancer (P =
0.007 by univariate analysis; P = 0.006 by multivariate
analysis). This "poor prognosis" signature was then tested
on an independent set of 104 ERα-positive breast tumors
from a well-defined cohort of postmenopausal breast can-
cer patients treated with primary surgery followed by
adjuvant tamoxifen alone. It was found to be significant
in univariate analysis (P = 0.029), but not in multivariate
analysis (P = 0.27). We have previously published individ-
ual data for 18 of these 47 genes, namely ERBB1-4 [12];
MYC [13]; TERT [14]; CCND1 [15]; CGB, CGA, ERα, ERβ,
PR, PS2 [16]; AR [17]; DNMT3B [18], PAI1, PAI2 and UPA
[19], obtained using the same real-time RT-PCR method
but in a heterogeneous series of 130 ERα-positive and
ERα-negative breast tumors.
Large-scale real-time quantitative RT-PCR is a promising
complement and/or alternative to cDNA microarrays for
molecular tumor profiling. CDNA microarrays have been
used to identify gene expression profiles associated with
poor outcome in breast cancer [20-26], but discrepancies
have been reported. For example, only 2 of 456 genes
identified by Sorlie et al. [21] was among the 70 genes
identified by van de Vijver et al. [24].
These discrepancies may be due to the clinical, histologi-
cal and ethnic heterogeneity of breast cancer, but also to
the fact that breast tumors consist of many different cell
types – not just tumoral epithelial cells, but also addi-
tional epithelial cell types, stromal cells, endothelial cells,
adipose cells, and infiltrating lymphocytes. Real-time RT-
PCR requires smaller starting amounts of total RNA
(about 1–2 ng per target gene) than do cDNA microarrays,
Table 5: Relationships between the prognostic (+/- relapses) and the mRNA levels of BRCA2, DNMT3B and CCNE1 in 104 ERα-positive 
postmenopausal breast tumors
GENES Tumors without relapses (n = 73) Tumors with relapses (n = 31) Pa ROC-AUCb
BRCA2 4.7 (1.0–23.6c 7.5 (1.4–38.4) 0.0018 0.694 (0.58–0.80)d
DNMT3B 3.6 (1.0–27.8) 6.2 (2.3–74.1) 0.00052 0.716 (0.61–0.82)
CCNE1 6.4 (1.0–46.2) 9.0 (1.3–62.8) 0.028 0.636 (0.51–0.76)
a:P value, Mann-Whitney U test.
b:ROC (Receiver Operating Characteristics) – AUC (Area Under Curve) analysis
c:Median (range) of gene mRNA levels
d:AUC value (95% confidence interval)Molecular Cancer 2004, 3:37 http://www.molecular-cancer.com/content/3/1/37
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making it more suitable for analyzing small tumor sam-
ples, cytopuncture specimens and microdissected sam-
ples. Real-time RT-PCR also has a linear dynamic range of
at least four orders of magnitude, meaning that samples
do not need to contain equal starting amounts of RNA.
Real-time RT-PCR is also more suitable than cDNA micro-
arrays for analyzing weak variations in gene expression
and weakly expressed genes (e.g. TERT as in the present
study), and for distinguishing among closely related
family member genes or alternatively spliced specific tran-
scripts (e.g. the gene cluster p14/ARF, p16/CDKN2A and
p15/CDKN2B as in the present study). Finally, real-time
quantitative RT-PCR assay is a reference in terms of its per-
formance, accuracy, sensitivity and throughput for nucleic
acid quantification, and is more appropriate for routine
use in clinical laboratories, being simple, rapid and yield-
ing good inter-laboratory agreement and statistical confi-
dence values.
In this study, we chose to include well known genes
involved in breast carcinogenesis reported in the literature
and representing a broad range of cellular functions, such
as cell cycle control, cell-cell interactions, signal transduc-
tion pathways, apoptosis and angiogenesis (Table 3).
Many important genes were not studied, but our results
nevertheless demonstrate the usefulness of real time RT-
PCR by identifying a potentially useful gene expression
signature with prognostic significance.
The comparison of median target gene mRNA levels
between patients who did and did not relapse provided
two interesting results: (a) ERBB2 mRNA levels were very
similar between the two subgroups, with ROC-AUC
values close to 0.5 (ROC-AUC, 0.573), confirming that
the ERBB2 mRNA expression level is not a major prognos-
tic factor in breast cancer; (b) ESR1/ERα  mRNA levels
were not different between the two subgroups (ROC-
AUC, 0.530), suggesting that the ESR1/ERα mRNA expres-
sion level in ERα-positive tumors is not predictive of
outcome.
The three-gene expression signature predictive of subse-
quent relapse status comprised genes involved in cell cycle
control (CCNE1), DNA methylation (DNMT3B) and
DNA damage repair (BRCA2). This gene expression signa-
ture is an interesting candidate for routine clinical use,
especially as the three genes encode well-characterized
proteins for which specific antibodies are already com-
mercially available. Furthermore, the three protein prod-
ucts are amenable to pharmacological control.
CCNE1 codes for cyclin E, a protein involved in regulating
the early G1 to late G1 phase "restriction point traversal",
an irreversible commitment to undergo one cell division
[27]. We found that high CCNE1  mRNA levels were
associated with poor outcome, confirming published data
suggesting that cyclin E upregulation may be a major
prognostic marker in breast cancer [28-31].
BRCA2 codes for a ubiquitously expressed tumor suppres-
sor protein involved in processes fundamental to all cells,
including DNA repair, DNA recombination and cell cycle
checkpoint control [32]. We found that high BRCA2
mRNA levels were associated with poor outcome and cor-
related positively and strongly with cell proliferation. By
hierarchical clustering analysis of the 47 genes, we identi-
fied BRCA2 as the leading gene in a cluster of proliferation
genes also including TERT, BRCA1, HMMR/RHAMM and
MKI67 (data not shown). We also observed a strong pos-
itive link between BRCA2 and MKI67, which encodes the
proliferation-related Ki-67 antigen (Spearman rank corre-
lation test: r=+0.670, P < 10-7). The observed strong asso-
ciations between BRCA2,  HMMR/RHAMM  and  MKI67
mRNA expression explain why four- and five-gene expres-
sion signatures, comprising HMMR/RHAMM  alone or
together with MKI67, showed no additional prognostic
value relative to the three-gene signature.
Our results for BRCA2 expression ex vivo are in keeping
with reports from several authors [33,34] showing that
BRCA2 mRNA expression is upregulated in rapidly prolif-
erating cells in vitro. Our results are also in agreement with
those of Egawa et al. [35] showing that high BRCA2
expression carries a poor prognosis in breast cancer. This
link between BRCA2 overexpression and poor outcome
should be taken into account when evaluating future
BRCA2-based therapeutic approaches to breast cancer.
Finally, DNMT3B, the third gene in our expression signa-
ture, codes for one of the three functional DNA methyl-
transferases (DNMT1,  DNMT3A  and  DNMT3B) that
catalyze the transfer of methyl groups to the 5-position of
cytosine (DNA methylation). We previously showed that,
among the three DNA methyltransferases (DNMT1,
DNMT3A and DNMT3B), only DNMT3B overexpression
is associated with poor outcome in breast cancer [18].
DNMT3B (like DNMT3A) is known to be a de novo meth-
ylator of CpG sites. Abnormal DNA methylation is
thought to be a major early event in the development of
tumors characterized by widespread genome hypomethyl-
ation leading to chromosome instability and localized
DNA hypermethylation; the latter may be important in
tumorigenesis by silencing tumor suppressor genes [36].
Conclusions
In conclusion, by studying the expression of 47 genes pre-
viously identified as candidate prognostic markers in
breast cancer, we identified a three-gene expression signa-
ture (BRCA2, DNMT3B and CCNE1) with prognostic sig-Molecular Cancer 2004, 3:37 http://www.molecular-cancer.com/content/3/1/37
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nificance. The practical value of this signature remains to
be validated in large prospective randomized studies.
Abbreviations
ERα, estrogen receptor alpha; RT-PCR, reverse tran-
scriptase-polymerase chain reaction.
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